In vitro Cytotoxic Effects of Sertraline on Normal Cells

Document Type : Original paper

Authors

1 Department of Clinical Psychology, Faculty of Medical Sciences, Tonekabon Branch, Islamic Azad University, Tonekabon, Iran

2 Department of Biology, Faculty of Advanced Sciences and Technologies, Tehran Medical Branch, Islamic Azad University, Tehran, Iran

3 Department of Agricultural Sciences and Food Industry, Science and Research Branch, Islamic Azad University, Tehran, Iran

Abstract

Background and aim: Studies have shown the cytotoxic effects of sertraline on various cells; however, the results are significantly contradictory. Accordingly, the present study investigated the cytotoxic effects of sertraline on normal human embryonic kidney (Hek293) cells. Materials and methods: In this experimental-laboratory study, Hek293 cells were divided into control group (no sertraline treatment) and sertraline treatment groups (1.56, 3.12, 6.25, 12.5, 25, 50 and 100 μg / ml). Cell viability was assessed by MTT 24 and 48 hours after sertraline treatment. Data were analyzed using one-way analysis of variance. Results: Treatment with 1.56 and 3.12 μg / ml of sertraline for 24 hours had no significant effect on the Hek-293 cells viability, however, the concentrations ≥6.25 μg / ml of sertraline significantly reduced the cell viability. Treatment of cells for 48 hours significantly reduced cell viability at concentrations ≥3.12 μg / ml of sertraline. Conclusion: The results of this study showed that sertraline can have a cytotoxic effect on non[1]cancerous cells and this effect depends on the dose and duration of treatment. This finding is important from sertraline side effects points of view on normal cells of the body considering its dose and period of consumption

Keywords


[1]. Stepanenko AA, Dmitrenko VV. HEK293 in cell biology and cancer research: phenotype, karyotype, tumorigenicity, and stress-induced genome-phenotype evolution. Gene. 2015;569(2):182-90.
[2]. Huddart R, Hicks JK, Ramsey LB, Strawn JR, Smith DM, Babilonia MB, Altman RB, Klein TE. PharmGKB summary: sertraline pathway, pharmacokinetics. Pharmacogenetics and genomics. 2020;30(2):26.
[3]. Bau-Carneiro JL, Sumida IA, Gallon M, Zaleski T, Boia-Ferreira M, Cavassin FB. Sertraline repositioning: an overview of its potential use as a chemotherapeutic agent after four decades of tumor reversal studies. Translation oncology. 2022;16:101303.
[4]. Khodashahri F. The cytotoxic effects of sertraline on ovarian (A2780) cancer cells in vitro. Journal of Biological Studies. 2022;5(1):120-7.
[5]. Bielecka AM, Obuchowicz E. Antidepressant drugs can modify cytotoxic action of temozolomide. European Journal of Cancer Care. 2017;26(5):e12551.
[6]. Molin CZ, Sakae TM, Schuelter-Trevisol F, Trevisol DJ. Effects of sertraline in the prevention of low blood pressure in patients undergoing hemodialysis. Brazilian Journal of Nephrology. 2019;41:492-500.
[7]. Jamshidi S, Hajian S, Rastgoo N, Mohammadi N. Comparison of the effects of sertraline and L-carnitine on intradialytic hypotension; a double blind clinical trial. Journal of Renal Injury Prevention. 2020;9(3):e22.
[8]. Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society. 1997;12(5):756-9.
[9]. Gowri M, Jayashree B, Jeyakanthan J, Girija EK. Sertraline as a promising antifungal agent: inhibition of growth and biofilm of Candida auris with special focus on the mechanism of action in vitro. Journal of applied microbiology. 2020;128(2):426-37.
[10]. Micó JA, Ardid D, Berrocoso E, Eschalier A. Antidepressants and pain. Trends in pharmacological sciences. 2006;27(7):348-54.
[11]. Damo E, Rieder P, Coban I, Silva RL, Kirchhoff F, Simonetti M, Agarwal A. Glial cells astarget for antidepressants in neuropathic pain. Neuroforum. 2022;28(2):85-94.
[12]. Lozano AF, Moura MS, Tavares BM, Kempinas WD. Exposure of pregnant rats to stress and/or sertraline: Side effects on maternal health and neurobehavioral development of male offspring. Life Sciences. 2021;285:119960.
[13]. Kelly K, Posternak M, Jonathan EA. Toward achieving optimal response: understanding and managing antidepressant side effects. Dialogues in clinical neuroscience. 2022.
[14]. Taler M, Miron O, Gil-Ad I, Weizman A. Neuroprotective and procognitive effects of sertraline: in vitro and in vivo studies. Neuroscience Letters. 2013;550:93-7.
[15]. Baharav E, Bar M, Taler M, Gil-Ad I, Karp L, Weinberger A, Weizman A. Immunomodulatory effect of sertraline in a rat model of rheumatoid arthritis. Neuroimmunomodulation. 2012;19(5):309-18.
[16]. Peng Q, Masuda N, Jiang M, Li Q, Zhao M, Ross CA, Duan W. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Experimental neurology. 2008;210(1):154-63.
[17]. Jajoo A, Donlon C, Shnayder S, Levin M, McVey M. Sertraline induces DNA damage and cellular toxicity in Drosophila that can be ameliorated by antioxidants. Scientific Reports. 2020;10(1):1-2.
[18]. Chen S, Xuan J, Couch L, Iyer A, Wu Y, Li QZ, Guo L. Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014;322:78-88
Volume 1, Issue 3
(Special Issue: papers selected from ICLS22, Istanbul, Turkey)
  • Receive Date: 03 October 2022
  • Revise Date: 10 October 2022
  • Accept Date: 15 October 2022